Currently held
- Agent 8 — Dip Buyer (Peer-Aware)long4 sh @ $269.39 · stop $247.84-$10.66 unrealized
COR
Cencora IncHealth Caresp500Last close $264.69May 31, 2026
Day −1.73%
Everything we've seen
- ·Jun 2, 9:21 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 9:21 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 8:50 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 8:50 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 8:21 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 8:21 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 7:50 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 7:50 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 7:36 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 7:36 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 7:20 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 7:20 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ?Jun 2, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.04 cash available; close=$264.69.
- !Jun 2, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $2.27 cash available; close=$264.70.
- ·Jun 2, 6:50 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 6:50 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 6:36 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 6:36 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 6:20 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 6:20 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 5:50 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 5:50 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 5:35 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 5:35 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 5:20 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 5:20 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 5:06 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 5:06 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 4:50 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 4:50 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 4:35 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 4:35 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 4:20 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 4:20 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ·Jun 2, 3:50 AMstreamnews
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ·Jun 2, 3:50 AMstreamnews
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ❖Jun 1, 7:11 PMnewsvia finnhub
Is Cencora’s New CFO, $2 Billion Buyback, and Lawsuit Trio Altering The Investment Case For Cencora (COR)?
Cencora has appointed Eva C. Boratto as Executive Vice President and Chief Financial Officer effective June 29, 2026, announced a share repurchase program of up to US$2.00 billion, and is facing a new California labor class action lawsuit. The combination of a seasoned healthcare-focused finance leader joining the company and a very large buyback authorization creates an important moment for reassessing Cencora’s capital allocation and governance profile. We’ll now examine how the...
- ?Jun 1, 6:03 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distribution company with stable, defensive cash flows and a long track record of resilience across economic cycles. The 16.1% drop from the 30-day high lacks any identifiable company-specific catalyst in the available evidence — no negative headlines, no concerning SEC filings — suggesting the move may be driven by macro rotation or broader market pressure. However, the elevated T10Y3M spread (0.89, 2.2σ above trend) signals tightening financial conditions that could weigh on risk assets broadly, even defensives, and the absence of any news makes it difficult to rule out an undisclosed fundamental issue.
- !Jun 1, 6:03 PMsignalseverity 0.19
Agent 4 — Dip Buyer (Frozen) — dip_skipped
COR (Cencora) is a large-cap pharmaceutical distribution company with stable, defensive cash flows and a long track record of resilience across economic cycles. The 16.1% drop from the 30-day high lacks any identifiable company-specific catalyst in the available evidence — no negative headlines, no concerning SEC filings — suggesting the move may be driven by macro rotation or broader market pressure. However, the elevated T10Y3M spread (0.89, 2.2σ above trend) signals tightening financial conditions that could weigh on risk assets broadly, even defensives, and the absence of any news makes it difficult to rule out an undisclosed fundamental issue.
- ?Jun 1, 6:03 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.27 cash available; close=$264.70.
- !Jun 1, 6:03 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Net signal score: +1. COR (Cencora) is down 17.9% from its 30-day high, triggering a mean-reversion positive signal (+1), and there are no earnings in the visible window (+1). However, the options flow is bearish — put volume is unusually elevated (P/C ratio 2.31, put z=-2.67) which is a meaningful negative signal (-1), and the Health Care sector has been underperforming SPY by 5.86pts over 30 days, suggesting broad sector pressure rather than single-stock idiosyncratic deterioration — this is a mild positive but partially offset by the sector flow proxy showing significant outflows today. No insider activity, no SEC filings with fundamental red flags, and VIX at the 19th percentile is benign. The 10Y at 4.45% is just below the headwind threshold, neutral for a defensive healthcare distributor like COR. No hard vetoes fired. With a net score of +1, no fundamental impairment, and a 55-60% base rate anchor, the probability is calibrated slightly below base rate due to the unusual put flow overhang.
- ❖Jun 1, 2:39 PMnewsvia finnhub
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.
- ❖Jun 1, 7:05 AMnewsvia finnhub
CDT May 2026 - 1999 Called, They Want Their Stock Market Back
The pre-2026 AI phenom was sparked by the introduction of ChatGPT. The post-May 2026 era is different. We may also be simultaneously mimicking the Pets.com phase with the SpaceX IPO.
- ✓Jun 1, 7:03 AMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
Net signal score: +1. COR (Cencora) is down 17.9% from its 30-day high, triggering a mean-reversion positive signal (+1), and there are no earnings in the visible window (+1). However, the options flow is bearish — put volume is unusually elevated (P/C ratio 2.31, put z=-2.67) which is a meaningful negative signal (-1), and the Health Care sector has been underperforming SPY by 5.86pts over 30 days, suggesting broad sector pressure rather than single-stock idiosyncratic deterioration — this is a mild positive but partially offset by the sector flow proxy showing significant outflows today. No insider activity, no SEC filings with fundamental red flags, and VIX at the 19th percentile is benign. The 10Y at 4.45% is just below the headwind threshold, neutral for a defensive healthcare distributor like COR. No hard vetoes fired. With a net score of +1, no fundamental impairment, and a 55-60% base rate anchor, the probability is calibrated slightly below base rate due to the unusual put flow overhang.
- ❖Jun 1, 3:00 AMnewsvia finnhub
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
- ✓May 29, 6:03 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
Wanted to buy but only $97.41 cash available; close=$267.71.
- ?May 29, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.04 cash available; close=$267.71.
- !May 29, 7:02 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $12.25 cash available; close=$267.61.
- ?May 29, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $97.41 cash available; close=$267.71.
- !May 29, 7:01 AMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $29.69 cash available; close=$267.61.
- ?May 28, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $12.25 cash available; close=$267.61.
- !May 28, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $1.29 cash available; close=$267.01.
- ?May 28, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distribution company with stable, defensive cash flows and a long track record of resilience across economic cycles. The 16.1% drop from the 30-day high lacks any identifiable company-specific catalyst in the available evidence — no negative headlines, no concerning SEC filings — suggesting the move may be driven by macro rotation or broader market pressure. However, the elevated T10Y3M spread (0.89, 2.2σ above trend) signals tightening financial conditions that could weigh on risk assets broadly, even defensives, and the absence of any news makes it difficult to rule out an undisclosed fundamental issue.
- !May 28, 6:01 PMsignalseverity 0.18
Agent 4 — Dip Buyer (Frozen) — dip_skipped
COR (Cencora) is a large-cap pharmaceutical distribution company with stable, defensive cash flows and a long track record of resilience across economic cycles. The 16.1% drop from the 30-day high lacks any identifiable company-specific catalyst in the available evidence — no negative headlines, no concerning SEC filings — suggesting the move may be driven by macro rotation or broader market pressure. However, the elevated T10Y3M spread (0.89, 2.2σ above trend) signals tightening financial conditions that could weigh on risk assets broadly, even defensives, and the absence of any news makes it difficult to rule out an undisclosed fundamental issue.
- ?May 28, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $29.69 cash available; close=$267.61.
- !May 28, 6:01 PMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $129.26 cash available; close=$267.01.
- ?May 28, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.29 cash available; close=$267.01.
- !May 28, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$267.01.
- ?May 28, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $129.26 cash available; close=$267.01.
- !May 28, 7:01 AMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $50.13 cash available; close=$267.01.
- ?May 27, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$267.01.
- ?May 27, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distribution company with stable, defensive cash flows and a long track record of resilience across economic cycles. The 16.1% drop from the 30-day high lacks any identifiable company-specific catalyst in the available evidence — no negative headlines, no concerning SEC filings — suggesting the move may be driven by macro rotation or broader market pressure. However, the elevated T10Y3M spread (0.89, 2.2σ above trend) signals tightening financial conditions that could weigh on risk assets broadly, even defensives, and the absence of any news makes it difficult to rule out an undisclosed fundamental issue.
- !May 27, 6:01 PMsignalseverity 0.19
Agent 4 — Dip Buyer (Frozen) — dip_skipped
COR (Cencora) is a large-cap pharmaceutical distribution company with stable, defensive cash flows and a long track record of resilience across economic cycles. The 16.1% drop from the 30-day high lacks any identifiable company-specific catalyst in the available evidence — no negative headlines, no concerning SEC filings — suggesting the move may be driven by macro rotation or broader market pressure. However, the elevated T10Y3M spread (0.89, 2.2σ above trend) signals tightening financial conditions that could weigh on risk assets broadly, even defensives, and the absence of any news makes it difficult to rule out an undisclosed fundamental issue.
- !May 27, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$270.78.
- ?May 27, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $50.13 cash available; close=$267.01.
- !May 27, 6:01 PMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $21.36 cash available; close=$270.78.
- ❖May 27, 7:14 AMnewsvia finnhub
Cencora nabs ex-CVS exec as new CFO
Eva Boratto, who spent more than a decade at CVS in a variety of finance roles, will join the drug distributor later this summer, Cencora announced Wednesday.
- ?May 27, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$270.78.
- !May 27, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $22.31 cash available; close=$270.84.
- ?May 27, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $21.36 cash available; close=$270.78.
- !May 27, 7:01 AMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $2.08 cash available; close=$270.84.
- ❖May 27, 6:55 AMnewsvia finnhub
Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
CONSHOHOCKEN, Pa., May 27, 2026--Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition.
- ❖May 27, 2:56 AMnewsvia finnhub
Cencora Appoints Eva C. Boratto As EVP And CFO
Cencora, Inc. (NYSE:COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms. Boratto succeeds James F. Cleary, who will be
- ?May 26, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distribution company with stable, defensive cash flows and a long track record of resilience across economic cycles. The 16.1% drop from the 30-day high lacks any identifiable company-specific catalyst in the available evidence — no negative headlines, no concerning SEC filings — suggesting the move may be driven by macro rotation or broader market pressure. However, the elevated T10Y3M spread (0.89, 2.2σ above trend) signals tightening financial conditions that could weigh on risk assets broadly, even defensives, and the absence of any news makes it difficult to rule out an undisclosed fundamental issue.
- ?May 26, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $22.31 cash available; close=$270.84.
- !May 26, 6:01 PMsignalseverity 0.17
Agent 4 — Dip Buyer (Frozen) — dip_skipped
COR (Cencora) is a large-cap pharmaceutical distribution company with stable, defensive cash flows and a long track record of resilience across economic cycles. The 16.1% drop from the 30-day high lacks any identifiable company-specific catalyst in the available evidence — no negative headlines, no concerning SEC filings — suggesting the move may be driven by macro rotation or broader market pressure. However, the elevated T10Y3M spread (0.89, 2.2σ above trend) signals tightening financial conditions that could weigh on risk assets broadly, even defensives, and the absence of any news makes it difficult to rule out an undisclosed fundamental issue.
- !May 26, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$274.91.
- ?May 26, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $2.08 cash available; close=$270.84.
- !May 26, 6:01 PMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$274.91.
- ?May 26, 9:22 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COR is up 3.57% intraday with no attributable headline, suggesting real institutional flow drove the move. COR is a healthcare/distribution defensive name, which tends to be resilient in a flattening yield curve environment (T10Y2Y at 0.43, below trend) — macro context is not a headwind here. With 384 minutes remaining (this appears to be near open or early session), there is ample time for continuation. However, the absence of a catalyst and the already-large magnitude of the move (near the top of a typical daily range for this ticker) raises some mean-reversion risk. No reversal pattern is evident from the data provided, and the system's bounded downside (-1.5% stop) favors a mild lean toward continuation. Probability is set modestly above 0.5 reflecting ordinary momentum without a strong confirming catalyst but no reason to expect a fade.
- !May 26, 9:22 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
COR is up 3.57% intraday with no attributable headline, suggesting real institutional flow drove the move. COR is a healthcare/distribution defensive name, which tends to be resilient in a flattening yield curve environment (T10Y2Y at 0.43, below trend) — macro context is not a headwind here. With 384 minutes remaining (this appears to be near open or early session), there is ample time for continuation. However, the absence of a catalyst and the already-large magnitude of the move (near the top of a typical daily range for this ticker) raises some mean-reversion risk. No reversal pattern is evident from the data provided, and the system's bounded downside (-1.5% stop) favors a mild lean toward continuation. Probability is set modestly above 0.5 reflecting ordinary momentum without a strong confirming catalyst but no reason to expect a fade.
- ?May 26, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$274.91.
- !May 26, 7:03 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Net signal score: +1. Positive signals: drop magnitude ≥15% from 30-day high without identified fundamental cause (+1), no earnings within visible window (+1), sector underperforming SPY on a 30-day basis (-7.99pts, suggesting sector-wide rather than idiosyncratic pressure) (+1). Negative signals: put/call ratio of 2.11 on the most recent trading day is elevated and skewed heavily toward puts, indicating bearish options positioning on a dipping stock (-1); 10Y yield at 4.57% is modestly above the ~4.5% threshold and COR (Cencora/AmerisourceBergen) is a healthcare distributor — relatively defensive but not entirely rate-immune (-1). No insider activity, no filings, and no headlines leave the picture data-light; macro is neutral-to-mild headwind with VIX at a calm 16.76 (40th percentile, no penalty). Net: +3 positives, -2 negatives = +1. Marginal territory with no strong confirming anchor signal (no cluster buy, no unusual call flow), so a buy is not supported per framework rules. However, COR as a large-cap healthcare distributor has durable fundamentals, and the base rate for a 16%+ dip in a sound name recovering within 90 days is ~55-60%; the elevated put flow and absence of any confirming insider/call signal trim this to ~0.52.
- ?May 26, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$274.91.
- !May 26, 7:02 AMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
COR (Cencora) is a large-cap pharmaceutical distributor with stable, recurring revenue and solid fundamentals — the drop of 16.2% from its 30-day high appears macro/sector-driven rather than tied to any confirmed fundamental impairment, as there are no negative news headlines, no adverse SEC filings, and no insider sales. The Health Care sector has underperformed SPY by ~8pts over 30 days, suggesting this is a broad sector pullback rather than idiosyncratic deterioration, which improves mean-reversion odds. However, the options flow is notably bearish (P/C ratio of 2.11 with put volume at nearly 2.1x call volume, though both are below average z-scores), and there are no confirmation signals such as insider buying or unusual call activity to support a stronger conviction buy.
- ?May 22, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COR (Cencora) is a large-cap healthcare distributor — a defensive, value-oriented name that is not particularly rate-sensitive, so the elevated 10Y yield (4.57%) is largely neutral here. The stock is down 16.1% from its 30-day high, which qualifies as a meaningful mean-reversion candidate, and there are no earnings imminent, no recent filings with adverse disclosures, and no insider selling. However, the options flow is distinctly bearish: the P/C ratio of 2.11 is flagged as UNUSUAL, driven by put volume at a z-score of -2.07 (below normal absolute volume but the elevated ratio signals directional put positioning), which is a meaningful negative signal suggesting informed hedging or downside bets. The Health Care sector is also a weak relative performer (rank 7 of 11, -7.99pts vs SPY over 30 days), which is a mild positive (sector-wide drag rather than idiosyncratic), but the sector has not been in outright freefall. No cluster insider buying is present to provide a strong contrarian signal.
- !May 22, 6:01 PMsignalseverity 0.16
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COR (Cencora) is a large-cap healthcare distributor — a defensive, value-oriented name that is not particularly rate-sensitive, so the elevated 10Y yield (4.57%) is largely neutral here. The stock is down 16.1% from its 30-day high, which qualifies as a meaningful mean-reversion candidate, and there are no earnings imminent, no recent filings with adverse disclosures, and no insider selling. However, the options flow is distinctly bearish: the P/C ratio of 2.11 is flagged as UNUSUAL, driven by put volume at a z-score of -2.07 (below normal absolute volume but the elevated ratio signals directional put positioning), which is a meaningful negative signal suggesting informed hedging or downside bets. The Health Care sector is also a weak relative performer (rank 7 of 11, -7.99pts vs SPY over 30 days), which is a mild positive (sector-wide drag rather than idiosyncratic), but the sector has not been in outright freefall. No cluster insider buying is present to provide a strong contrarian signal.
- ?May 22, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distribution company with stable, defensive cash flows and a long track record of resilience across economic cycles. The 16.1% drop from the 30-day high lacks any identifiable company-specific catalyst in the available evidence — no negative headlines, no concerning SEC filings — suggesting the move may be driven by macro rotation or broader market pressure. However, the elevated T10Y3M spread (0.89, 2.2σ above trend) signals tightening financial conditions that could weigh on risk assets broadly, even defensives, and the absence of any news makes it difficult to rule out an undisclosed fundamental issue.
- !May 22, 6:01 PMsignalseverity 0.16
Agent 4 — Dip Buyer (Frozen) — dip_skipped
COR (Cencora) is a large-cap pharmaceutical distribution company with stable, defensive cash flows and a long track record of resilience across economic cycles. The 16.1% drop from the 30-day high lacks any identifiable company-specific catalyst in the available evidence — no negative headlines, no concerning SEC filings — suggesting the move may be driven by macro rotation or broader market pressure. However, the elevated T10Y3M spread (0.89, 2.2σ above trend) signals tightening financial conditions that could weigh on risk assets broadly, even defensives, and the absence of any news makes it difficult to rule out an undisclosed fundamental issue.
- ?May 22, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distributor with historically stable cash flows and a defensible business model, so the 16.1% drop from its 30-day high is more likely macro/sector-driven than a fundamental impairment — no negative headlines, SEC filings, or insider sales are present to confirm deterioration. However, the Health Care sector is underperforming SPY on a 30-day basis (-7.99pts), suggesting this is partly a sector-wide move that could reverse with rotation back into healthcare. The options flow is notably bearish — an elevated P/C ratio of 2.11 with unusual put volume (z=-2.07) on the most recent trading day raises caution, though this could reflect hedging activity rather than directional conviction. With no confirmed negative catalyst but a meaningful put-flow warning signal and elevated 10Y yields (4.57%) providing a valuation headwind, evidence is mixed and does not clearly favor a high-conviction buy.
- !May 22, 6:01 PMsignalseverity 0.16
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
COR (Cencora) is a large-cap pharmaceutical distributor with historically stable cash flows and a defensible business model, so the 16.1% drop from its 30-day high is more likely macro/sector-driven than a fundamental impairment — no negative headlines, SEC filings, or insider sales are present to confirm deterioration. However, the Health Care sector is underperforming SPY on a 30-day basis (-7.99pts), suggesting this is partly a sector-wide move that could reverse with rotation back into healthcare. The options flow is notably bearish — an elevated P/C ratio of 2.11 with unusual put volume (z=-2.07) on the most recent trading day raises caution, though this could reflect hedging activity rather than directional conviction. With no confirmed negative catalyst but a meaningful put-flow warning signal and elevated 10Y yields (4.57%) providing a valuation headwind, evidence is mixed and does not clearly favor a high-conviction buy.
- ?May 22, 2:31 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COR is up ~4% intraday with no attributable headline, suggesting this is likely a large institutional flow or sector rotation event. The move is meaningful and represents real conviction. However, several factors temper the continuation probability: (1) With only 75 minutes remaining until the forced close, there is limited runway for additional upside to compound — much of the move may already be complete. (2) The macro backdrop shows T10Y3M at +2.2σ above trend, which signals a steepening yield curve environment. COR (Cencora, a healthcare/pharma distributor) is not directly in the banks or recession-sensitive bucket flagged as reactive, so macro is broadly neutral to slightly irrelevant here. (3) No news catalyst means we cannot confirm whether this is a one-time event (merger rumor, earnings pre-announcement, block trade) or sustained buying pressure — absence of news slightly increases fade risk at this late stage. (4) A 4% move in a large-cap defensive distributor is unusual and may attract profit-taking as the session closes. Balancing the inherent momentum bias, the bounded risk structure, and the time/magnitude considerations, I assign a modest continuation edge above 0.5 but not strong enough to classify as high-conviction.
- !May 22, 2:31 PMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
COR is up ~4% intraday with no attributable headline, suggesting this is likely a large institutional flow or sector rotation event. The move is meaningful and represents real conviction. However, several factors temper the continuation probability: (1) With only 75 minutes remaining until the forced close, there is limited runway for additional upside to compound — much of the move may already be complete. (2) The macro backdrop shows T10Y3M at +2.2σ above trend, which signals a steepening yield curve environment. COR (Cencora, a healthcare/pharma distributor) is not directly in the banks or recession-sensitive bucket flagged as reactive, so macro is broadly neutral to slightly irrelevant here. (3) No news catalyst means we cannot confirm whether this is a one-time event (merger rumor, earnings pre-announcement, block trade) or sustained buying pressure — absence of news slightly increases fade risk at this late stage. (4) A 4% move in a large-cap defensive distributor is unusual and may attract profit-taking as the session closes. Balancing the inherent momentum bias, the bounded risk structure, and the time/magnitude considerations, I assign a modest continuation edge above 0.5 but not strong enough to classify as high-conviction.
- ?May 22, 11:35 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COR is up 2.91% intraday with 250 minutes remaining — substantial time left for continuation. The move is meaningful in magnitude, suggesting real institutional flow rather than noise. No headlines are available, but absence of news is not a disqualifier; large moves often precede public disclosure. The macro context shows T10Y3M at 2.2σ above trend, which is modestly favorable for healthcare/distribution names like COR (less recession-sensitive than banks), creating no clear headwind. However, without a clear catalyst or volume confirmation data, the setup is ordinary momentum rather than a high-conviction continuation. The yield curve steepening slightly benefits risk assets broadly. With ample time remaining and no reversal signals noted, the base case is mild continuation, but the lack of a specific catalyst or sector tailwind keeps confidence moderate rather than elevated.
- !May 22, 11:35 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
COR is up 2.91% intraday with 250 minutes remaining — substantial time left for continuation. The move is meaningful in magnitude, suggesting real institutional flow rather than noise. No headlines are available, but absence of news is not a disqualifier; large moves often precede public disclosure. The macro context shows T10Y3M at 2.2σ above trend, which is modestly favorable for healthcare/distribution names like COR (less recession-sensitive than banks), creating no clear headwind. However, without a clear catalyst or volume confirmation data, the setup is ordinary momentum rather than a high-conviction continuation. The yield curve steepening slightly benefits risk assets broadly. With ample time remaining and no reversal signals noted, the base case is mild continuation, but the lack of a specific catalyst or sector tailwind keeps confidence moderate rather than elevated.
- ?May 22, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COR (Cencora) is a large-cap healthcare distributor — a defensive, value-oriented name — that has dropped 20.2% from its 30-day high, a magnitude consistent with a mean-reversion candidate (+1). No earnings are visible in the window (+1), and the sector is broadly underperforming the market (ranked 10 of 11 by 30d relative strength, -12.48pts vs SPY over 30 days), suggesting this is sector-wide pressure rather than an idiosyncratic company issue (+1). However, the options flow on 2026-05-18 shows a notably elevated put/call ratio of 1.57 with put volume (3,110) significantly exceeding call volume (1,977), a bearish signal (-1). There is no insider buying, no positive fundamental catalyst, and the 10Y yield at 4.59% is a mild headwind even for defensive names (-1). Inflation expectations (T10YIE at 2.4σ above trend) add macro uncertainty for the sector. Net signal score: +3 positive, -2 negative = +1, which is marginal without a strong insider or unusual call signal to tip the balance.
- !May 22, 7:01 AMsignalseverity 0.19
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COR (Cencora) is a large-cap healthcare distributor — a defensive, value-oriented name — that has dropped 20.2% from its 30-day high, a magnitude consistent with a mean-reversion candidate (+1). No earnings are visible in the window (+1), and the sector is broadly underperforming the market (ranked 10 of 11 by 30d relative strength, -12.48pts vs SPY over 30 days), suggesting this is sector-wide pressure rather than an idiosyncratic company issue (+1). However, the options flow on 2026-05-18 shows a notably elevated put/call ratio of 1.57 with put volume (3,110) significantly exceeding call volume (1,977), a bearish signal (-1). There is no insider buying, no positive fundamental catalyst, and the 10Y yield at 4.59% is a mild headwind even for defensive names (-1). Inflation expectations (T10YIE at 2.4σ above trend) add macro uncertainty for the sector. Net signal score: +3 positive, -2 negative = +1, which is marginal without a strong insider or unusual call signal to tip the balance.
- ?May 22, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distributor with typically stable fundamentals, so the company itself is likely sound. However, the 21.4% drop has no identifiable catalyst from available evidence — no news, no filings, no insider activity — which makes it difficult to assess whether this is a macro/sector-driven selloff or something more fundamental. The sector (Health Care / XLV) is ranked 10 of 11 by 30-day relative strength, down 13.87pts vs SPY, indicating broad sector weakness that may be dragging COR down with it. That said, the options flow is notably bearish: a P/C ratio of 1.95 on the most recent trading day signals elevated put activity relative to calls, suggesting near-term directional pessimism rather than hedging on a recovery thesis.
- !May 22, 7:01 AMsignalseverity 0.19
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
COR (Cencora) is a large-cap pharmaceutical distributor with typically stable fundamentals, so the company itself is likely sound. However, the 21.4% drop has no identifiable catalyst from available evidence — no news, no filings, no insider activity — which makes it difficult to assess whether this is a macro/sector-driven selloff or something more fundamental. The sector (Health Care / XLV) is ranked 10 of 11 by 30-day relative strength, down 13.87pts vs SPY, indicating broad sector weakness that may be dragging COR down with it. That said, the options flow is notably bearish: a P/C ratio of 1.95 on the most recent trading day signals elevated put activity relative to calls, suggesting near-term directional pessimism rather than hedging on a recovery thesis.
- ?May 21, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COR (Cencora) is a large-cap healthcare distributor — a defensive, value-oriented name — that has dropped 20.2% from its 30-day high, a magnitude consistent with a mean-reversion candidate (+1). No earnings are visible in the window (+1), and the sector is broadly underperforming the market (ranked 10 of 11 by 30d relative strength, -12.48pts vs SPY over 30 days), suggesting this is sector-wide pressure rather than an idiosyncratic company issue (+1). However, the options flow on 2026-05-18 shows a notably elevated put/call ratio of 1.57 with put volume (3,110) significantly exceeding call volume (1,977), a bearish signal (-1). There is no insider buying, no positive fundamental catalyst, and the 10Y yield at 4.59% is a mild headwind even for defensive names (-1). Inflation expectations (T10YIE at 2.4σ above trend) add macro uncertainty for the sector. Net signal score: +3 positive, -2 negative = +1, which is marginal without a strong insider or unusual call signal to tip the balance.
- !May 21, 6:01 PMsignalseverity 0.19
Agent 5 — Dip Buyer (Evolving) — dip_skipped
COR (Cencora) is a large-cap healthcare distributor — a defensive, value-oriented name — that has dropped 20.2% from its 30-day high, a magnitude consistent with a mean-reversion candidate (+1). No earnings are visible in the window (+1), and the sector is broadly underperforming the market (ranked 10 of 11 by 30d relative strength, -12.48pts vs SPY over 30 days), suggesting this is sector-wide pressure rather than an idiosyncratic company issue (+1). However, the options flow on 2026-05-18 shows a notably elevated put/call ratio of 1.57 with put volume (3,110) significantly exceeding call volume (1,977), a bearish signal (-1). There is no insider buying, no positive fundamental catalyst, and the 10Y yield at 4.59% is a mild headwind even for defensive names (-1). Inflation expectations (T10YIE at 2.4σ above trend) add macro uncertainty for the sector. Net signal score: +3 positive, -2 negative = +1, which is marginal without a strong insider or unusual call signal to tip the balance.
- ?May 21, 6:00 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distributor with typically stable fundamentals, so the company itself is likely sound. However, the 21.4% drop has no identifiable catalyst from available evidence — no news, no filings, no insider activity — which makes it difficult to assess whether this is a macro/sector-driven selloff or something more fundamental. The sector (Health Care / XLV) is ranked 10 of 11 by 30-day relative strength, down 13.87pts vs SPY, indicating broad sector weakness that may be dragging COR down with it. That said, the options flow is notably bearish: a P/C ratio of 1.95 on the most recent trading day signals elevated put activity relative to calls, suggesting near-term directional pessimism rather than hedging on a recovery thesis.
- !May 21, 6:00 PMsignalseverity 0.19
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
COR (Cencora) is a large-cap pharmaceutical distributor with typically stable fundamentals, so the company itself is likely sound. However, the 21.4% drop has no identifiable catalyst from available evidence — no news, no filings, no insider activity — which makes it difficult to assess whether this is a macro/sector-driven selloff or something more fundamental. The sector (Health Care / XLV) is ranked 10 of 11 by 30-day relative strength, down 13.87pts vs SPY, indicating broad sector weakness that may be dragging COR down with it. That said, the options flow is notably bearish: a P/C ratio of 1.95 on the most recent trading day signals elevated put activity relative to calls, suggesting near-term directional pessimism rather than hedging on a recovery thesis.
- ?May 21, 6:00 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COR (Cencora, formerly AmerisourceBergen) is a large-cap pharmaceutical distribution company with stable, recurring revenue and historically resilient fundamentals. The 20.2% drop from its 30-day high is notable, but the absence of any news headlines or recent SEC filings suggests no company-specific deterioration; the move may reflect broader sector rotation or macro pressure. The macro context shows elevated inflation expectations (T10YIE at 2.4σ above trend), which can pressure healthcare distribution margins modestly via higher financing costs, but COR's business model is relatively insulated from long-duration rate sensitivity.
- ?May 21, 11:47 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COR (Cencora, formerly AmerisourceBergen) is a large-cap pharmaceutical distribution company with stable, recurring revenue and historically resilient fundamentals. The 20.2% drop from its 30-day high is notable, but the absence of any news headlines or recent SEC filings suggests no company-specific deterioration; the move may reflect broader sector rotation or macro pressure. The macro context shows elevated inflation expectations (T10YIE at 2.4σ above trend), which can pressure healthcare distribution margins modestly via higher financing costs, but COR's business model is relatively insulated from long-duration rate sensitivity.
- ?May 21, 11:47 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COR (Cencora) is a large-cap healthcare distributor — a defensive, value-oriented name — that has dropped 20.2% from its 30-day high, a magnitude consistent with a mean-reversion candidate (+1). No earnings are visible in the window (+1), and the sector is broadly underperforming the market (ranked 10 of 11 by 30d relative strength, -12.48pts vs SPY over 30 days), suggesting this is sector-wide pressure rather than an idiosyncratic company issue (+1). However, the options flow on 2026-05-18 shows a notably elevated put/call ratio of 1.57 with put volume (3,110) significantly exceeding call volume (1,977), a bearish signal (-1). There is no insider buying, no positive fundamental catalyst, and the 10Y yield at 4.59% is a mild headwind even for defensive names (-1). Inflation expectations (T10YIE at 2.4σ above trend) add macro uncertainty for the sector. Net signal score: +3 positive, -2 negative = +1, which is marginal without a strong insider or unusual call signal to tip the balance.
- ?May 21, 11:46 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distributor with typically stable fundamentals, so the company itself is likely sound. However, the 21.4% drop has no identifiable catalyst from available evidence — no news, no filings, no insider activity — which makes it difficult to assess whether this is a macro/sector-driven selloff or something more fundamental. The sector (Health Care / XLV) is ranked 10 of 11 by 30-day relative strength, down 13.87pts vs SPY, indicating broad sector weakness that may be dragging COR down with it. That said, the options flow is notably bearish: a P/C ratio of 1.95 on the most recent trading day signals elevated put activity relative to calls, suggesting near-term directional pessimism rather than hedging on a recovery thesis.
- ?May 21, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distributor with typically stable fundamentals, so the company itself is likely sound. However, the 21.4% drop has no identifiable catalyst from available evidence — no news, no filings, no insider activity — which makes it difficult to assess whether this is a macro/sector-driven selloff or something more fundamental. The sector (Health Care / XLV) is ranked 10 of 11 by 30-day relative strength, down 13.87pts vs SPY, indicating broad sector weakness that may be dragging COR down with it. That said, the options flow is notably bearish: a P/C ratio of 1.95 on the most recent trading day signals elevated put activity relative to calls, suggesting near-term directional pessimism rather than hedging on a recovery thesis.
- ?May 21, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COR (Cencora) is a large-cap healthcare distributor — a defensive, value-oriented name — that has dropped 20.2% from its 30-day high, a magnitude consistent with a mean-reversion candidate (+1). No earnings are visible in the window (+1), and the sector is broadly underperforming the market (ranked 10 of 11 by 30d relative strength, -12.48pts vs SPY over 30 days), suggesting this is sector-wide pressure rather than an idiosyncratic company issue (+1). However, the options flow on 2026-05-18 shows a notably elevated put/call ratio of 1.57 with put volume (3,110) significantly exceeding call volume (1,977), a bearish signal (-1). There is no insider buying, no positive fundamental catalyst, and the 10Y yield at 4.59% is a mild headwind even for defensive names (-1). Inflation expectations (T10YIE at 2.4σ above trend) add macro uncertainty for the sector. Net signal score: +3 positive, -2 negative = +1, which is marginal without a strong insider or unusual call signal to tip the balance.
- ?May 20, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COR (Cencora, formerly AmerisourceBergen) is a large-cap pharmaceutical distribution company with stable, recurring revenue and historically resilient fundamentals. The 20.2% drop from its 30-day high is notable, but the absence of any news headlines or recent SEC filings suggests no company-specific deterioration; the move may reflect broader sector rotation or macro pressure. The macro context shows elevated inflation expectations (T10YIE at 2.4σ above trend), which can pressure healthcare distribution margins modestly via higher financing costs, but COR's business model is relatively insulated from long-duration rate sensitivity.
- ?May 20, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COR (Cencora) is a large-cap healthcare distributor — a defensive, value-oriented name — that has dropped 20.2% from its 30-day high, a magnitude consistent with a mean-reversion candidate (+1). No earnings are visible in the window (+1), and the sector is broadly underperforming the market (ranked 10 of 11 by 30d relative strength, -12.48pts vs SPY over 30 days), suggesting this is sector-wide pressure rather than an idiosyncratic company issue (+1). However, the options flow on 2026-05-18 shows a notably elevated put/call ratio of 1.57 with put volume (3,110) significantly exceeding call volume (1,977), a bearish signal (-1). There is no insider buying, no positive fundamental catalyst, and the 10Y yield at 4.59% is a mild headwind even for defensive names (-1). Inflation expectations (T10YIE at 2.4σ above trend) add macro uncertainty for the sector. Net signal score: +3 positive, -2 negative = +1, which is marginal without a strong insider or unusual call signal to tip the balance.
- ?May 20, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distributor with typically stable fundamentals, so the company itself is likely sound. However, the 21.4% drop has no identifiable catalyst from available evidence — no news, no filings, no insider activity — which makes it difficult to assess whether this is a macro/sector-driven selloff or something more fundamental. The sector (Health Care / XLV) is ranked 10 of 11 by 30-day relative strength, down 13.87pts vs SPY, indicating broad sector weakness that may be dragging COR down with it. That said, the options flow is notably bearish: a P/C ratio of 1.95 on the most recent trading day signals elevated put activity relative to calls, suggesting near-term directional pessimism rather than hedging on a recovery thesis.
- ?May 20, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distributor with typically stable fundamentals, so the company itself is likely sound. However, the 21.4% drop has no identifiable catalyst from available evidence — no news, no filings, no insider activity — which makes it difficult to assess whether this is a macro/sector-driven selloff or something more fundamental. The sector (Health Care / XLV) is ranked 10 of 11 by 30-day relative strength, down 13.87pts vs SPY, indicating broad sector weakness that may be dragging COR down with it. That said, the options flow is notably bearish: a P/C ratio of 1.95 on the most recent trading day signals elevated put activity relative to calls, suggesting near-term directional pessimism rather than hedging on a recovery thesis.
- ?May 20, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COR (Cencora) is a large-cap healthcare distributor — a defensive, value-oriented name — that has dropped 20.2% from its 30-day high, a magnitude consistent with a mean-reversion candidate (+1). No earnings are visible in the window (+1), and the sector is broadly underperforming the market (ranked 10 of 11 by 30d relative strength, -12.48pts vs SPY over 30 days), suggesting this is sector-wide pressure rather than an idiosyncratic company issue (+1). However, the options flow on 2026-05-18 shows a notably elevated put/call ratio of 1.57 with put volume (3,110) significantly exceeding call volume (1,977), a bearish signal (-1). There is no insider buying, no positive fundamental catalyst, and the 10Y yield at 4.59% is a mild headwind even for defensive names (-1). Inflation expectations (T10YIE at 2.4σ above trend) add macro uncertainty for the sector. Net signal score: +3 positive, -2 negative = +1, which is marginal without a strong insider or unusual call signal to tip the balance.
- ?May 19, 6:02 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
COR (Cencora) is a large-cap healthcare distributor — a defensive, value-oriented name — that has dropped 20.2% from its 30-day high, a magnitude consistent with a mean-reversion candidate (+1). No earnings are visible in the window (+1), and the sector is broadly underperforming the market (ranked 10 of 11 by 30d relative strength, -12.48pts vs SPY over 30 days), suggesting this is sector-wide pressure rather than an idiosyncratic company issue (+1). However, the options flow on 2026-05-18 shows a notably elevated put/call ratio of 1.57 with put volume (3,110) significantly exceeding call volume (1,977), a bearish signal (-1). There is no insider buying, no positive fundamental catalyst, and the 10Y yield at 4.59% is a mild headwind even for defensive names (-1). Inflation expectations (T10YIE at 2.4σ above trend) add macro uncertainty for the sector. Net signal score: +3 positive, -2 negative = +1, which is marginal without a strong insider or unusual call signal to tip the balance.
- ?May 19, 6:02 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
COR (Cencora) is a large-cap pharmaceutical distributor with typically stable fundamentals, so the company itself is likely sound. However, the 21.4% drop has no identifiable catalyst from available evidence — no news, no filings, no insider activity — which makes it difficult to assess whether this is a macro/sector-driven selloff or something more fundamental. The sector (Health Care / XLV) is ranked 10 of 11 by 30-day relative strength, down 13.87pts vs SPY, indicating broad sector weakness that may be dragging COR down with it. That said, the options flow is notably bearish: a P/C ratio of 1.95 on the most recent trading day signals elevated put activity relative to calls, suggesting near-term directional pessimism rather than hedging on a recovery thesis.
- ?May 19, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COR (Cencora, formerly AmerisourceBergen) is a large-cap pharmaceutical distribution company with stable, recurring revenue and historically resilient fundamentals. The 20.2% drop from its 30-day high is notable, but the absence of any news headlines or recent SEC filings suggests no company-specific deterioration; the move may reflect broader sector rotation or macro pressure. The macro context shows elevated inflation expectations (T10YIE at 2.4σ above trend), which can pressure healthcare distribution margins modestly via higher financing costs, but COR's business model is relatively insulated from long-duration rate sensitivity.
- ?May 19, 2:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COR is up 2.07% intraday with no attributable headline, suggesting this is flow/technical driven rather than news-driven. The move is meaningful but not extreme. Macro context shows elevated 10Y inflation expectations (T10YIE at 2.4σ above trend), which is a mild headwind for long-duration sensitive sectors; however, COR (Cencora, a healthcare distributor) has limited direct sensitivity to long-duration rate moves — its cash flows are relatively near-term and defensive. No reversal signals are apparent from the data provided. With 75 minutes remaining there is reasonable time for continuation, but not a wide window. The absence of news is neutral per guidance. Overall, no strong reason to fade this move, but also no clear catalyst to drive further acceleration — a modest continuation probability is appropriate.
- ?May 19, 1:01 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COR is up ~1.87% with 164 minutes remaining — a meaningful move but below the 2-5% 'high conviction' threshold. No headlines are present to explain the move, suggesting either quiet sector rotation or institutional accumulation without a catalyst. The macro context shows T10YIE elevated at 2.4σ above trend, indicating higher inflation expectations. COR (Cencora, a healthcare distribution company) is generally a defensive, non-duration-sensitive name, meaning the macro headwind from elevated real rates is minimal for this sector. With no catalyst to fade and no reversal pattern indicated, the default lean is modest continuation. However, the move is not large enough and the macro context is not tailwind-strong enough to warrant high conviction. Time remaining is ample (164 min), so there is room to run. Assigning a slight edge to continuation on the basis of momentum persistence in a defensive name with neutral macro exposure and no counter-catalyst visible.
- ?May 19, 11:10 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
COR is up 2.59% intraday with no headline catalyst identified, suggesting this is likely institutional flow or sector rotation rather than news-driven noise. With 275 minutes remaining (roughly 4.5 hours, essentially a full trading day remaining), there is ample time for continuation. COR is a healthcare distribution/services company (McKesson-adjacent sector), which is generally not a long-duration sensitive sector, meaning the elevated T10YIE (2.4σ above trend) macro headwind is largely irrelevant here — healthcare distribution tends to be defensive and rate-insensitive. The absence of news is not disqualifying per the framework. The move magnitude (2.59%) is meaningful and suggests real conviction from a sizable participant. No reversal pattern is indicated in the data provided. The main uncertainty is the lack of any corroborating catalyst or volume confirmation, keeping this from a higher-conviction read. On balance, the momentum and time remaining support a modest continuation bias.
- ?May 19, 9:28 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
COR (Cencora, formerly AmerisourceBergen) is a large-cap pharmaceutical distribution company with stable, recurring revenue and historically resilient fundamentals. The 20.2% drop from its 30-day high is notable, but the absence of any news headlines or recent SEC filings suggests no company-specific deterioration; the move may reflect broader sector rotation or macro pressure. The macro context shows elevated inflation expectations (T10YIE at 2.4σ above trend), which can pressure healthcare distribution margins modestly via higher financing costs, but COR's business model is relatively insulated from long-duration rate sensitivity.
- ▢May 13, 8:00 PMjournal
Agent 7 — Day Trader opened long 7 @ $258.78
- ▣May 13, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 7 @ $260.90 (+$14.88)
EOD forced close — day trader never carries overnight